| Literature DB >> 29922482 |
Weina Ma1, Liu Yang1, Langchong He1.
Abstract
Drug-receptor interaction plays an important role in a series of biological effects, such as cell proliferation, immune response, tumor metastasis, and drug delivery. Therefore, the research on drug-receptor interaction is growing rapidly. The equilibrium dissociation constant (KD) is the basic parameter to evaluate the binding property of the drug-receptor. Thus, a variety of analytical methods have been established to determine the KD values, including radioligand binding assay, surface plasmon resonance method, fluorescence energy resonance transfer method, affinity chromatography, and isothermal titration calorimetry. With the invention and innovation of new technology and analysis method, there is a deep exploration and comprehension about drug-receptor interaction. This review discusses the different methods of determining the KD values, and analyzes the applicability and the characteristic of each analytical method. Conclusively, the aim is to provide the guidance for researchers to utilize the most appropriate analytical tool to determine the KD values.Entities:
Keywords: Affinity chromatography; Drug-receptor interaction; Equilibrium dissociation constant; FRET; RBA; SPR
Year: 2018 PMID: 29922482 PMCID: PMC6004624 DOI: 10.1016/j.jpha.2018.05.001
Source DB: PubMed Journal: J Pharm Anal ISSN: 2214-0883
The RBA method and application examples.
| No. | Receptor | Drug | Receptor material | References | |
|---|---|---|---|---|---|
| 1 | Glycine transporter-1 | CHIBA-3007 | Rat brain membranes | 1.61 (±0.16)×10−9 M | |
| 2 | α7 nicotinic acetylcholine receptors | CHIBA-1006 | Rat brain membranes | 88.2 (±21.4)×10−9 M | |
| 3 | Opioid receptor | TICP[psi] | Rat brain membranes | 0.35×10−9 M | |
| 4 | 5-HT(1A) receptors | WAY100635 | Rat hippocampal membranes | 87 (±4)×10−12 M | |
| 5 | Dopamine D1 receptor | SCH23390 | Sheep brain striatum membranes | 56 (±8)×10−9 M | |
| 6 | Histamine H3 receptor | Thioperamide | Rat cerebral cortex | 0.80 (±0.06)×10−9 M | |
| 7 | Adenosine A2A receptors | ZM241385 | Rat striatum membranes | 0.14×10−9 M | |
| Transfected CHO cell membranes | 0.23×10−9 M | ||||
| 8 | Platelet-activating factor (PAF) receptor | L-659,989 | Rabbit platelet membranes | 1.60 (±0.20)×10−9 M | |
| 9 | Bradykinin B2 receptors | PIP HOE 140 | Guinea pig ileal membranes | 15×10−12 M | |
| 10 | Thromboxane (TP-) receptor | GR32191 | Human platelets membranes | 2.1×10−9 M | |
| Human platelets | 2.2×10−9 M | ||||
| 11 | Human angiotensin II AT1 receptor | Olmesartan | CHO-hAT(1) cells | 0.091×10−9 M | |
| Telmisartan | 0.12×10−9 M | ||||
| 12 | Glucocorticoid receptor | Dexamethasone | Peripheral blood mononuclear cells | 66.194×10−9 M | |
| 13 | Histamine H1-receptors | Mepyramine | Bovine retinal blood vessels | 2.78 (±0.32)×10−9 M | |
| 14 | Calcium channels | Nitrendipine | Rat brain synaptosomes | 0.35×10−9 M | |
| 15 | NK1 receptor | CP96,345 | Guinea pig lung | 0.12 (±0.03)×10−9 M | |
| 16 | vasopressin V2-receptors | DDAVP | Rat kidney | 0.76×10−9 M |
The SPR method and application examples.
| No. | Receptor | Drug | Receptor material | References | |
|---|---|---|---|---|---|
| 1 | EGFR | EGF | EGFR protein | 0.177×10−6 M | |
| GE11 | 0.459×10−3 M | ||||
| mAb LA1 | 2.07×10−9 M | ||||
| 2 | Subendothelial collagens | vWf | Purified protein | 2.03(±0.04)×10−9 M | |
| 3 | Pr55(Gag) | 1,4,5-IP3 | Purified protein | 2170×10−6 M | |
| di-C(8)-PI | 186×10−6 M | ||||
| di-C(8)-PI(4,5)P2 | 47.4×10−6 M | ||||
| 4 | VEGFR2 D3 | Nanobody against NTV(1–4) | HUVEC cell | 49(±1.8)×10−9 M | |
| 5 | CD56 | Monoclonal antibodies m900 | Cancer cell | 2.9×10−9 M | |
| Monoclonal antibodies m906 | 4.5×10−9 M | ||||
| 6 | Grp1 PH domain | Biotinylated Ins(1,3,4,5)P4 | Rat brain membranes | 0.14×10−6 M | |
| 7 | Angiotensin converting enzyme | Lisinopril | Angiotensin converting enzyme | 1.78×10−9 M | |
| 8 | rKDR1–3 | VEGF165 | rKDR1–3 protein | 57.4×10−9 M | |
| 9 | Lipoprotein lipase | Bis-ANS | Purified protein | (0.10−0.26)×10−6 M | |
| 10 | CL-43 | Yeast mannan | Purified protein | (2.68−2.72)×10−8 M | |
| 11 | Human glycophorin A | Nanobody IH4 | Human glycophorin A | 33×10−9 M | |
| 12 | Cyclophilin A | Trp-Gly-Pro | Cyclophilin A | 3.41×10−6 M | |
| 13 | Collagen glycoprotein VI | GABA | Human platelets | 41.4×10−9 M |
The affinity chromatography method and application examples.
| No. | Receptor | Drug | Receptor material | References | |
|---|---|---|---|---|---|
| 1 | Estrogen receptor | Diethylstilbestrol | Purified protein | ERRγ, 237×10−9 M | |
| ERRα, 929×10−9 M | |||||
| 2 | α3β4nicotinic acetylcholine receptor | Dextromethorphan | α3β4-nAChR cell membrane | Ka:23.40(± 0.36)×106 M−1 | |
| Levomethorphan | Ka:12.01(± 0.23)×106 M−1 | ||||
| 3 | Cannabinoid receptor CB1 | Win-55, MA, ACEA | KU-812 cell membrane | (8.6±8.3) × 10−9 M, (19.8±10.9) × 10−9 M, (0.74±0.22) × 10−9 M | |
| Cannabinoid receptor CB2 | (0.37±0.12) × 10−9 M, (653 ± 182) × 10−9 M, (5200 ±2.5) × 10−9 M | ||||
| 4 | PKCα | Chelerythrine | Purified protein | 698×10−9 M | |
| 5 | μ opioid receptors | Naloxone | CHO-μ opioid receptors cell membrane | 110×10−9 M | |
| κ opioid receptors | U69593 | CHO-κ opioid receptors cell membrane | 84×10−9 M | ||
| 6 | L-type calcium channel | Nifedipine | VSMC | (3.36±0.28)×10−6 M | |
| Nimodipine | (1.34±0.15)×10−6 M | ||||
| Nitrendipine | (6.83±0.48)×10−7 M | ||||
| Nicardipine | (1.23±0.16)×10−7 M | ||||
| Amlodipine | (1.09±0.09)×10−7 M | ||||
| Verapamil | (8.51±0.61)×10−8 M | ||||
| 7 | α1A adrenoreceptor | Tamsulosin | α1A/HEK293 cell membrane | (1.87±0.13)×10−6 M | |
| 5-methylurapidil | (2.86±0.20)×10−6 M | ||||
| Doxazosin | (3.01±0.19)×10−6 M | ||||
| Terazosin | (3.44±0.19)×10−6 M | ||||
| Alfuzosin | (3.50±0.21)×10−6 M | ||||
| 8 | Histamine H1 receptor | Azelastine | H1R/HEK293 cell membrane | (8.72±0.21)×10−7 M | |
| Cyproheptadine | (9.12±0.26)×10−7 M | ||||
| Doxipine | (9.90±0.18)×10−7 M | ||||
| Astemizole | (1.42±0.13)×10−6 M | ||||
| Chlorpheniramine | (2.25±0.36)×10−6 M | ||||
| Diphenhydramine | (3.10±0.27)×10−6 M |